PARK; Bum-Chan

Patent Applications and Registrations

Patent applications and USPTO patent grants for PARK; Bum-Chan.The latest application filed is for "anti-vsig4 antibody or antigen binding fragment and uses thereof".

Company Profile

15.10.14

PARK; Bum-Chan - DAEJEON KR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Anti-vsig4 Antibody Or Antigen Binding Fragment And Uses Thereof App 20220306736 - LOUKILI; Noureddine ; et al.	2022-09-29
Antibody against human DLK1 and use thereof Grant 11,306,141 - Lim , et al. April 19, 2	2022-04-19
BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO IL-17A AND TNF-Alpha App 20220098297 - YOON; Jae Bong ; et al.	2022-03-31
Antibody to programmed cell death 1 (PD-1) and use thereof Grant 11,248,048 - Park , et al. February 15, 2	2022-02-15
Monoclonal Antibody Specifically Binding To Lag-3 And Use Thereof App 20210238283 - LEE; Sang Pil ; et al.	2021-08-05
Antibody Against Human DLK1 and Use Thereof App 20210214432 - Lim; Jung Chae ; et al.	2021-07-15
Antibody to programmed death-ligand 1 (PD-L1) and use thereof Grant 10,919,966 - Park , et al. February 16, 2	2021-02-16
Cell engaging binding molecules Grant 10,836,833 - Jang , et al. November 17, 2	2020-11-17
Cell Engaging Binding Molecules App 20200181288 - JANG; Seil ; et al.	2020-06-11
Cell engaging binding molecules Grant 10,654,944 - Jang , et al.	2020-05-19
Cell engaging binding molecules Grant 10,640,576 - Jang , et al.	2020-05-05
Cell engaging binding molecules Grant 10,633,458 - Jang , et al.	2020-04-28
Novel Multi-specific Binding Proteins App 20190389973 - JANG; Seil ; et al.	2019-12-26
Cell Engaging Binding Molecules App 20190338029 - JANG; Seil ; et al.	2019-11-07
Antibody To Programmed Cell Death-ligand 1 (pd-l1) And Use Thereof App 20190322750 - Park; Jae Eun ; et al.	2019-10-24
Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of delta-like 1 homolog Grant 10,448,662 - Park , et al. Oc	2019-10-22
Cell Engaging Binding Molecules App 20190309094 - JANG; Seil ; et al.	2019-10-10
Cell Engaging Binding Molecules App 20190309093 - JANG; Seil ; et al.	2019-10-10
Antibody To Programmed Cell Death 1 (pd-1) And Use Thereof App 20190248900 - Park; Jae Eun ; et al.	2019-08-15
Anti-TNF-.alpha./CXCL10 double-targeting antibody and use thereof Grant 10,087,248 - Kang , et al. October 2, 2	2018-10-02
Composition for Preventing or Treating Fatty Liver or Insulin Resistance Syndrome Including Extracellular Domain of Delta-Like 1 Homolog App 20170121380 - Park; Young Woo ; et al.	2017-05-04
Myostatin inhibitor comprising extracellular water-soluble domains of DLK1 as active ingredient Grant 9,388,223 - Lee , et al. July 12, 2	2016-07-12
Anti-TNF-alpha/CXCL10 Double-Targeting Antibody and Use Thereof App 20160108118 - Kang; Heun-Soo ; et al.	2016-04-21
Myostatin Inhibitor Comprising Extracellular Water-Soluble Domains of DLK1 As Active Ingredient App 20150030595 - Lee; Dong Hee ; et al.	2015-01-29

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.